EXHIBIT A

                   GIVEN IMAGING ANNOUNCES FOURTH QUARTER AND
                              YEAR END 2002 RESULTS

              -Growth reflects significant progress on all fronts-


Yoqneam,  Israel,  February 12, 2003 - Given Imaging Ltd.  (NASDAQ:GIVN),  today
announced  fourth quarter and year end results for the period ended December 31,
2002.  The Company  reported  that  worldwide  sales of its Given(R)  Diagnostic
Imaging System and M2A video capsule grew to $28.9 million for the twelve months
ended December 31, 2002.  Revenues for the fourth quarter were $9.0 million,  up
20% from the third quarter, and 157% above the fourth quarter of 2001.

"2002 was a year of profound  achievement  for Given Imaging as we  accomplished
all of our major  milestones:  financial  reimbursement,  production and medical
community  acceptance.  We also invested significant  resources in expanding our
international sales and marketing  organization and global distribution network,
which covers now 50 countries" said Gavriel D. Meron, President and CEO of Given
Imaging.  "Most  importantly,  the medical  community now  recognizes  our Given
Diagnostic System as an essential diagnostic tool for detecting and diagnosing a
growing number of small bowel disorders. As we enter 2003, all of the pieces are
in place  to  build  broader  proliferation  of our  technology  and  value  for
shareholders. Our financial position is strong and we believe that we will reach
breakeven in the second half of this year."

On a geographic basis,  sales of the Given System in the United States accounted
for more than half of total annual revenues. A geographical  breakdown of annual
sales is as follows:

(millions of U.S. dollars)
-------------------------

United States     $15.7
Europe            $ 8.3
Rest of the World $ 4.9


Fourth Quarter and Full Year 2002 Financials

Revenues  totaled $9.0 million  during the fourth  quarter,  up from $7.5 in the
third quarter,  and $3.5 in the fourth quarter of 2001.  Gross profit was 66% of
revenues, up from 58.7% in the third quarter, and 50.6% in the fourth quarter of



<PAGE>


2001. Net loss for the fourth quarter was $3.7 million, or $0.15 per share, down
from a net loss of $4.0  million  in the  third  quarter  of 2002,  or $0.16 per
share, and $6.5 million in the fourth quarter of 2001, or $0.26.

For the year ended  December 31,  2002,  revenues  were $28.9  million and gross
profit was 59% of revenues. Net loss for the full year 2002 was $18.3 million or
$0.73 per share,  compared  to a net loss of $18.7  million in 2001 or $1.60 per
share ($0.74 per share on an adjusted,  post-initial  public  offering  basis of
25,104,913 shares).

By year-end 2002,  cumulative  deliveries of the Given Diagnostic System reached
more than 1,000, with more than 460 systems installed in the United States.

In light of the  concerns  regarding  any impact of an armed  conflict  in Iraq,
Given Imaging  reiterates its contingency supply  arrangements,  consisting of a
back-up  manufacturing  facility and strategic inventories of finished goods and
materials outside of Israel.


Fourth Quarter Highlights

During the fourth quarter, Given Imaging accomplished the following milestones:

     -    Sold  approximately  8,200 M2A  capsules,  of which  more  than  5,800
          represent reorders.  Cumulatively,  approximately  30,000 M2A capsules
          have  been  sold  to  date.
     -    Received an Ambulatory Payment  Classification (APC) from CMS (Centers
          for  Medicare & Medicaid)  for  capsule  endoscopy  for U.S.  Medicare
          patients  in an  outpatient  hospital  setting.  CMS also  assigned  a
          temporary  G  code  for  physicians  to  use  when  reporting  capsule
          endoscopy to Medicare.
     -    Saw further medical community acceptance as evidenced by the number of
          abstracts  and  sessions  devoted to capsule  endoscopy  at the United
          European  Gastroenterology  Week  (UEGW) in Geneva,  Switzerland,  the
          American  College  of  Gastroenterologists  (ACG)  Annual  Meeting  in
          Seattle,  Washington, and the Australian Gastro Week (AGW) this month.
          Data on nearly 1,700  patients was presented  showing  superiority  of
          capsule endoscopy over conventional  methods in diagnosing small bowel
          diseases   including   cancer,   Crohn's  disease,   gastro-intestinal
          bleeding,  inflammatory  bowel  disease  and celiac.
     -    Continued  the roll-out of the ASGE  sponsored  CME courses on capsule
          endoscopy  throughout  the United  States.
     -    Received  reimbursement  coverage  by The  Regence  Group  of  Oregon,
          Washington,  Utah and Idaho;  Blue Cross of  California;  Blue Cross &
          Blue Shield

<PAGE>

          of Rhode Island  Medicare and  HGSAdministrators  which is Highmark of
          Pennsylvania's government business unit for capsule endoscopy.

     -    Obtained  reimbursement  coverage  beyond  bleeding  for  patients who
          demonstrate  symptoms of Crohn's  disease or small  bowel  tumors that
          cannot  be  confirmed  by  other  methods  from  HGSAdministrators.
     -    Appointed,  Nancy Sousa, an industry  veteran as the new president for
          our  U.S.  operations.
     -    Grew  the U.S.  field  force  to 40  sales  professionals.
     -    Signed a  long-term  development  and  supply  agreement  with  Micron
          Technology  to provide CMOS image  sensors used in the M2A capsule.
     -    Launched  the Rapid 2 and  Booster to  support  new  features  such as
          Multiview  and  reporting   software  that  enhance  the   physician's
          efficiency in using the Given Diagnostic System.
     -    Received  regulatory  approval from the Russian  Federation
     -    Received the "Photonics Circle of Excellence"  award,  recognizing the
          25 most innovative New Products of the year 2002.

Guidance

Based on our positive fourth quarter and full year  performance,  the Company is
now prepared to issue guidance for the first time.

The Company  expects its revenues for 2003 to increase  approximately  100% over
2002 revenues of $28.9 million.

Looking  forward to the first quarter of 2003, the Company  expects its revenues
to increase  approximately  100% over its first  quarter  2002  revenues of $5.2
million.

The Company expects to reach breakeven and achieve sustainable  profitability in
the second half of 2003.

Fourth Quarter Webcast Information

Given Imaging will host a conference call tomorrow, Thursday, February 13, 2003,
at 9:00 am  Eastern  Standard  Time (4:00 pm Israel  time) to  discuss  its 2002
results.  The  conference  call will be webcast  through the  Company's  website
www.givenimaging.com.

About Given Imaging

Given  Imaging  develops,  produces and markets the Given(R)  Diagnostic  System
featuring the M2A(R) Capsule Endoscope,  the only non-invasive method for direct
visualization  of the  entire  small  intestine.  The system  uses a  disposable
miniature video camera  contained in a capsule which is ingested by the patient.
The M2A capsule passes naturally through the digestive tract,  transmitting high
quality color images,  without interfering with the patient's normal activities.
The  system  received  clearance  from  the  FDA in  August  2001  and  received
permission  to affix  the CE mark in May  2001.  Distribution  channels  for the
system have been  established in more than 50 countries  worldwide.  The M2A has

<PAGE>

been utilized to diagnose a range of diseases of the small  intestine  including
Crohn's Disease,  Celiac disease and other malabsorption  disorders,  benign and
malignant tumors of the small intestine, vascular disorders,  medication related
small bowel injury,  as well as a range of pediatric small bowel disorders.  For
more information, visit http://www.givenimaging.com.


This press release  contains  forward-looking  statements  about Given  Imaging,
including  projections about our business,  our future revenues,  and our future
profitability,  within the meaning of Section 27A of the  Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934. For example,  statements
in the  future  tense,  words  such as  "anticipates,"  "estimates,"  "expects,"
"intends," "plans," "believes," and words and terms of similar substance used in
connection  with any  discussion  of future  operating or financial  performance
identify such forward-looking  statements.  Those forward-looking statements are
not guarantees of future  performance and actual results could differ materially
from our current expectations as a result of numerous factors, including but not
limited to the  following:  changes in  regulatory  environment,  our success in
implementing  our  sales,  marketing  and  manufacturing  plan,  protection  and
validity  of  patents  and other  intellectual  property  rights,  the impact of
currency  exchange  rates,  the effect of  competition by other  companies,  the
outcome of future  litigation,  the reimbursement  policies for our product from
healthcare payors, quarterly variations in operating results, the possibility of
armed conflict or civil or military  unrest in Israel and other risks  disclosed
in our filings with the U.S. Securities Exchange Commission.

                                      # # #

                            (Financial tables follow)


<PAGE>



              Given Imaging Ltd. And Its Consolidated Subsidiaries
                           Consolidated Balance Sheets
                    U.S. $ in thousands except per share data

<TABLE>
<CAPTION>
                                                       December 31,     December 31,
                                                           2001             2002
                                                       ------------     ------------
                                                         (Audited)        (Audited)

<S>                                                     <C>             <C>
Assets


Cash and cash equivalents                                    $61,230           $35,792
Current assets                                                 7,729            20,267

                                                        ------------      ------------
Total current assets                                          68,959            56,059

Deposits and Assets held for severance benefits                  457               866

Fixed assets, net                                              5,104             9,967

Other assets, net                                              1,403             1,836

                                                        ------------      ------------
Total Assets                                                 $75,923           $68,728
                                                        ============      ============



Liabilities and shareholders' equity

Current liabilities                                            5,875            11,360
Deferred revenue                                                 193               727

                                                        ------------      ------------
Total current liabilities                                      6,068            12,087

Long-term liabilities                                            522               882

Minority interest                                                                2,182

Shareholders' equity                                          69,333            53,577

                                                        ------------      ------------
Total liabilities and shareholders' equity                   $75,923           $68,728
                                                        ============      ============

</TABLE>


<PAGE>


              Given Imaging Ltd. And Its Consolidated Subsidiaries
                      Consolidated Statements Of Operations
                    U.S.$ in thousands except per share data


<TABLE>
<CAPTION>
                                                     Year ended December 31,          Three month period
                                                    ---------------------------        ended December 31,
                                                      2001            2002           2001           2002
                                                    ---------      ------------   -----------    -----------
                                                    (Audited)      (Audited)      (Unaudited)    (Unaudited)
<S>                                                <C>             <C>               <C>          <C>
Revenues                                                $4,733         $28,904         $3,477         $9,050

Cost of revenues                                        (2,476)        (11,907)        (1,717)        (3,052)
                                                  ------------     ------------      ---------    -----------
Gross profit                                             2,257          16,997          1,760          5,998

Research and development costs                          (6,112)         (8,609)        (2,080)        (2,039)
Marketing expenses                                     (12,902)        (22,681)        (5,337)        (6,570)
General and administrative expenses                     (2,664)         (4,749)        (1,065)        (1,465)
                                                  ------------     ------------      ---------    -----------
Operating loss                                         (19,421)        (19,042)        (6,722)        (4,076)

Financing income, net                                      764           1,469            258            358
Other expenses, net                                                       (711)                           (4)

Minority share in (profits) loss of subsidiary                             (26)                           27
                                                  ------------     ------------      ---------    -----------
Net loss                                             $ (18,657)      $ (18,310)       $(6,464)       $(3,695)
                                                  =============    ============      =========    ===========

Basic and diluted loss per
 Ordinary Share                                         $(1.60)         $(0.73)        $(0.26)        $(0.15)
                                                  =============    ============      =========    ===========


Weighted average number of Ordinary Shares
outstanding used in basic and diluted loss per
Ordinary Share calculation                          12,879,369      25,182,563     25,104,913     25,241,113
                                                  =============    ============    ===========    ===========



Additional per share information:
--------------------------------

Diluted loss per ordinary share on
an as adjusted basis post public
offering.                                               $(0.74)
                                                  =============

Ordinary shares outstanding post
public offering                                     25,104,913
                                                  =============

</TABLE>

                                      # # #